arrow
M

Mario Sánchez-Salinas

vall d'hebron university hospital
H指数:5
被引数:177

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Consolidative allogeneic HCT vs. a watch-and-wait approach for B-cell acute lymphoblastic leukemia patients with early loss of B-cell aplasia after CAR T-cell therapy

巩固性同种异基因HCT与观察等待策略的比较:CAR T细胞治疗后早期丧失B细胞 aplasia的B细胞急性淋巴细胞白血病患者

2026-09-290
PRE
Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma

氟达拉滨暴露对大B细胞淋巴瘤患者CAR T细胞疗效的影响

2026-06-120
OAAI
EASIX Does Not Add Prognostic Value Beyond Lactate Dehydrogenase and ECOG Performance Status in CAR T-Cell Therapy: A GETH-TC Study

EASIX在CAR T细胞疗法中不增加超过乳酸脱氢酶和ECOG体力状态 prognostic value:一项GETH-TC研究

2026-01-010
PRE
Towards Personalized Lymphodepletion: A Population Pharmacokinetic Fludarabine Model in Patients Receiving CAR T-Cell Therapy

迈向个性化淋巴细胞清除:接受CAR T细胞疗法的患者群体药代动力学氟达拉滨模型

2025-12-100
OA
Efficacy and safety of bendamustine-containing bridging therapy in R/R LBCL patients receiving CD19 CAR T-cells
2024-06-260
OAAI